The funding amount provided should be reasonable to meet the above requirements. Many a time, the funds provided are unrealistic and inadequate. Subsidies of 20 to 30 per cent and concessional rate of interest of five per cent need to be considered. As the equipment and machineries will be mortgaged to the bank against the loan no other collateral securities should be insisted. Although Small Industries Development Bank of India (SIDBI) may be the nodal bank, the loan need to be disbursed through nationalised banks through a simple procedure.
The investment limits for pharma SMEs also need to be increased to accommodate the expansions required to meet global needs. The best platform for SMEs can be in contact manufacturing and exports. Tremendous opportunities are opening in exports and if pharma SMEs are encouraged through TUFS schemes, they can increase India’s share in supply of pharma to the world.
– SV Veerramani, President, Indian Drug Manufacturers Association (IDMA)